Thiele Sylvia, Baschant Ulrike, Rauch Alexander, Rauner Martina
Division of Endocrinology and Metabolic Bone Diseases, Department of Medicine III, Technical University Dresden , Dresden, Germany.
Department of Biochemistry and Molecular Biology, University of Southern Denmark , Odense, Denmark.
Bonekey Rep. 2014 Jul 2;3:552. doi: 10.1038/bonekey.2014.47. eCollection 2014.
Glucocorticoids are effective drugs used for the treatment of inflammatory diseases such as rheumatoid arthritis or asthma. Furthermore, they regulate various physiological processes, including bone remodeling. However, long-term high- and even low-dose glucocorticoid use is associated with a compromised bone quality and an increased fracture risk. At the cellular level, glucocorticoids suppress bone formation and stimulate bone resorption, which leads to loss of bone mass. To investigate the underlying mechanisms and new therapeutic strategies, the in vivo model for glucocorticoid-induced bone loss is widely used. This protocol outlines the common procedure that is currently used for the induction of bone loss in mice using glucocorticoids. It further provides useful hints and highlights possible pitfalls to take into account before starting an experiment.
糖皮质激素是用于治疗类风湿性关节炎或哮喘等炎症性疾病的有效药物。此外,它们还调节包括骨重塑在内的各种生理过程。然而,长期高剂量甚至低剂量使用糖皮质激素会导致骨质量受损和骨折风险增加。在细胞水平上,糖皮质激素抑制骨形成并刺激骨吸收,从而导致骨量流失。为了研究其潜在机制和新的治疗策略,糖皮质激素诱导性骨丢失的体内模型被广泛使用。本方案概述了目前用于使用糖皮质激素诱导小鼠骨丢失的常见程序。它还提供了有用的提示,并强调了在开始实验前需要考虑的可能陷阱。